业绩总结 - Teva的总收入预计从2022年的149亿美元增长至2024年的165亿美元，年均增长率为5.3%[24] - 2022年，Teva的仿制药收入为86亿美元，预计到2024年将增长至95亿美元[24] - Teva的整体收入增长（CAGR）预计在2022年至2027年期间为中个位数百分比[44] - 2024年，Teva的总收入预计为95亿美元，其中包括47亿美元来自于欧洲和国际市场的仿制药[187] 用户数据 - 美国Tardive Dyskinesia（TD）患者数量为785,000人，其中接受VMAT2i治疗的患者为120,000人[63] - 2024年美国和欧盟的精神分裂症患者总数约为240万人，其中接受LAI治疗的患者占比约为13%[83] - AUSTEDO XR的新增处方中约50%为未接受过治疗的VMAT2i患者[65] - UZEDY的患者满意度超过92%[124] 新产品和新技术研发 - AUSTEDO的收入预计在2027年达到超过25亿美元[47] - Teva的创新产品组合预计在2030年将超过50亿美元的收入目标，年均增长率约为30%[22] - Teva的创新产品线包括olanzapine LAI，预计在2025年下半年提交申请，峰值销售潜力为15亿至20亿美元[38] - 预计DARI（TEV-'248）将在2027年提交申请，针对哮喘的治疗[121] - olanzapine LAI（TEV-'749）预计在2025年下半年提交美国NDA申请[121] 市场扩张和并购 - Teva的仿制药业务在美国市场排名第一，欧洲市场排名前三[40] - Teva在2022年至2023年期间的欧盟市场份额为24%[193] - Teva在2022-2023年推出的产品中，市场份额在选择的17个欧洲市场中，平均市场份额为2114个产品中的635个Teva产品的3个季度后数据[196] - Teva在OTC市场的全球排名为第9位，专注于欧洲和国际市场[200] 负面信息 - Teva的净负债与调整后EBITDA比率为2.0倍，目标是到2027年实现30%的运营利润率[44] - 预计到2027年，仿制药收入中来自美国的比例将从33%降至25%[187] - 在接受治疗的UC患者中，最多有20%需要进行至少一次手术[129] - 在接受治疗的CD患者中，最多有75%需要进行至少一次手术[129] 其他新策略和有价值的信息 - Teva计划在2026年前实现约10%的支出减少，预计将节省约8%的员工人数[42] - Teva目前拥有10个在售资产，预计在2025-2027年将有约5个潜在产品推出，覆盖约200亿美元的失去独占权(LoE)价值[197] - Teva在OTC市场的收入分布中，消化系统和维生素矿物质补充剂(VMS)各占约10%[200] - Teva在疼痛管理领域的OTC市场份额为25%[200]

业绩总结 - Inotiv在2023财年总收入为572.4百万美元，较2022财年的547.7百万美元增长4.3%[9] - 预计2025财年的资本支出将占年收入的4.0%，低于过去五年的历史平均水平8%[31] - Inotiv在2023年实现了1700万至1900万美元的年度净节省，主要通过基础设施的优化和战略资本投资实现[11] 用户数据 - 截至2025年3月31日，Inotiv的客户中，北美占80%，EMEA占15%[23] - Inotiv的员工人数约为2100人，客户数量约为2200个[6] 新产品和新技术研发 - Inotiv在2023年完成了48,000平方英尺的马里兰新设施建设，以支持生物治疗和遗传毒理学的增长[33] 资本支出与投资 - 截至2025年4月30日，Inotiv已投资约990万美元于资本支出，主要用于动物福利和服务收入增长的设施改善[30] - 自2018年至2023年，Inotiv的资本支出超过1.13亿美元，预计未来资本支出将减少[27] 服务收入构成 - Inotiv的服务收入中，服务类占45%，大型动物研究占29%[13]

Q1 Results Presentation May 29, 2025 1 Cautionary Statement Regarding Forward-Looking Information This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our 2025 a ...

Fiscal Year 2025 Fourth Quarter and Full Year Results May 29, 2025 Today's Speakers Hamilton Lane | Global Leader in the Private Markets 2 Erik Hirsch Co-CEO Jeff Armbrister Chief Financial Officer John Oh Head of Shareholder Relations Period Highlights Business Performance Financial Results • Declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on June 20, 2025 1Adjusted net income, non-GAAP earnings per share, Fee Related Earnings and Adjusted ...

First Quarter 2025 Supplemental Financial Information May 29, 2025 1 General Disclaimer Forward-Looking Statements The matters discussed in this presentation, in the Company's press releases, and in the Company's website-accessible conference calls with analysts include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"), about the plans, strategies, objectives, goals or ...

Financial Results and Business Update for the Year Ended March 31, 2025 May 29, 2025 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business ...

May 29, 2025 1 Forward-Looking Statements This presentation contains "forward-looking" information within the meaning of the federal securities laws. The "forward-looking" information may include statements concerning the Company's outlook for the future as well as other statements of beliefs, future plans, strategies, or anticipated events and similar expressions concerning matters that are not historical facts. Words or phrases such as "should result," "believe," "intend," "plan," "are expected to," "targ ...

May 29, 2025 Q1 2025 EARNINGS & 2025 GUIDANCE 1 Q1 EARNINGS CALL PARTICIPANTS DANIEL HEAF Chief Executive Officer FORWARD-LOOKING STATEMENTS Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 We caution that any forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) contained in this report or made by our Company or our management involve risks and uncertainties and are subject to change based on various factors, many of whi ...

业绩总结 - 2025年第一季度总收入为人民币8900万元，同比增长38%[34] - 毛利润达到人民币5880万元，同比增长27%，毛利率提升520个基点[46][48] - 净亏损同比缩窄38%，显示出公司在控制支出方面的成效[54] 用户数据 - 客户数量实现环比增长25%[18] - 开发者服务的净美元留存率为96%，表明客户忠诚度高[30] 收入来源 - 开发者服务收入为人民币5350万元，连续三个季度收入超过5000万元[29] - 订阅服务收入同比增长26%，显示出海外市场的稳定增长[38] - EngageLab业务在第一季度新签合同总值超过人民币6300万元，累计合同价值超过人民币1.1亿元，同比增长132%[21] - 财务风险管理部门实现同比收入增长64%，创下历史最佳季度收入[29] 未来展望 - 延期收入达到历史最高水平，第一季度余额为人民币1.569亿元[57]

KeyBanc Industrials & Basic Materials Conference Boston, MA May 29, 2025 1 Today's Speakers Aaron Schapper President and Chief Executive Officer Dan Hoehn Vice President and Corporate Controller, Interim Chief Financial Officer Meghan Beringer Sr. Director, Investor Relations 2 Safe Harbor Statement & Non-GAAP Measures Statements in this presentation contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including i ...